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Organic nitrates, cornerstones of antianginal therapy, are be-
lieved to exert their principal anti-ischemic benefit by relaxing 
vascular smooth muscle. Recent evidence suggests that these 
compounds and related nitro(so) vasodilators are also potent 
platelet inhibitors. In view of the well recognized role of throm-
botic events mediated by platelets in acute coronary syndromes, 
In the past decade, significant strides have been made in our 
understanding of the pathogenesis of ischemic coronary 
syndromes. As a result, the pharmacotherapy of patients 
with coronary artery disease has undergone noticeable 
changes. Perhaps the most remarkable change has been the 
introduction of antiplatelet therapy into the pharmacopoeia 
of cardiovascular medicine. This development is the direct 
consequence of overwhelming evidence that platelets are 
protagonists in unstable angina (1-3), myocardial infarction 
(2,4,5), sudden death (2,4,6), vasospastic angina (7 ,8) and, 
perhaps, hypertensive disorders (9, 10). It is therefore note-
worthy that despite the evolution of our conceptual and 
therapeutic approach to patients with cardiovascular dis-
ease, nitrates have survived intensive scrutiny to remain as 
mainstays of therapy for acute coronary syndromes (3, 11-
13). 
Recent reviews (11, 14-17) as well as reputable current 
cardiovascular texts (18, 19) attribute the mechanism of the 
antiischemic action of nitrates and nitroprusside to their 
relaxant effects on vascular smooth muscle. Controversy 
persists as to the relative importance of coronary artery and 
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the antiplatelet effect of nitrates may also be of mechanistic 
importance in the treatment of these disorders. This review details 
the biochemical mechanism by which nitro(so) compounds inhibit 
platelet function and summarizes the in vitro and in vivo evidence 
that supports their antithrombotic effects. 
(JAm Coli Cardiol1991;18:1529-36) 
arteriole dilation versus peripheral vasodilation in alleviating 
myocardial ischemia (11,14,16); however, the antiplatelet 
effects of nitro-vasodilators receive no mention despite the 
substantial number of published reports that have accumu-
lated in this regard since the first demonstration (20) of the 
platelet inhibitory actions of nitroglycerin in 1967. Conse-
quently, the clinician is generally unaware of the anti platelet 
properties of organic nitrates and nitroprusside, and these 
agents are rarely considered part of the antiplatelet reper-
toire of cardiologists or potential contributors to iatrogenic 
bleeding diatheses (21). 
In this report, we review the antiplatelet properties of 
organic nitrates and nitroprusside in vitro and in vivo. These 
data suggest that the antiplatelet effects of nitro compounds 
are of clinical relevance and therefore likely contribute to 
their beneficial mechanism of action in the acute ischemic 
syndromes of unstable angina and acute myocardial infarc-
tion. 
Antiplatelet Effects of Organic Nitrates 
In Vitro 
Early studies (20,22,23) uniformly demonstrated that ni-
troglycerin inhibited platelet aggregation. One such study by 
Schafer et a!. (23) also revealed a weak platelet-inhibitory 
effect of isosorbide dinitrate. By that time, several investi-
gators (24-28) had already shown that nitroprusside directly 
inhibits platelet aggregation and promotes platelet disaggre-
gation. Thus, by 1980, each of the oxides of nitrogen 
commonly used in clinical practice had been demonstrated 
to exhibit antiplatelet properties in vitro. These findings 
notwithstanding, the concentrations of nitroglycerin and 
isosorbide dinitrate required to elicit inhibitory effects in 
vitro were not pharmacologically achievable in vivo and the 
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biochemical mechanism by which nitrates act on platelets 
was poorly understood. The subsequent inability of Mehta 
and Mehta (29) to demonstrate platelet inhibition during 
intravenous nitroglycerin infusions further called into ques-
tion the physiologic relevance of the in vitro findings. As we 
will discuss, however, each of these pertinent reservations 
about the relevance of the antiplatelet effects of organic 
nitrates and nitroprusside in vivo has now been addressed 
conclusively. 
Mechanism of Action 
Mellion et a!. (30) first delineated the role of cyclic 
guanosine monophosphate (GMP) in the mechanism of plate-
let inhibition by nitrogen oxides. Extensive investigations by 
their group (31 ,32) and others (33 ,34) led to the discovery 
that nitric oxide and related nitroso compounds activate 
guanylate cyclase in a variety of tissues by a molecular 
mechanism involving the interaction of nitric oxide with the 
enzyme's heme group. Additionally, several investigators 
(31 ,35-37) recognized the reduced thiol requirement for 
maximal expression of guanylate cyclase activity and sug-
gested that S-nitrosothiol adducts form as active intermedi-
ates in the metabolism of nitrates and related compounds. 
With this information in hand, Mellion et a!. (30) demon-
strated that nitric oxide and nitroprusside, which releases 
nitric oxide, inhibit platelet aggregation in association with 
marked increases in platelet cyclic GMP. These inhibitory 
responses were mimicked by the 8-bromo analogue of cyclic 
GMP and were prevented by methemoglobin, a hemoprotein 
with an affinity for nitric oxide. In later work, the same group 
(38) convincingly demonstrated the inhibitory potency of 
various synthetic S-nitrosothiols on human platelet aggrega-
tion and their activation of platelet guanylate cyclase in a 
heme-dependent manner. 
Role of reduced thiols. Loscalzo (39) subsequently ex-
tended these observations to the study of organic nitrates, 
demonstrating that the reduced thiol N-acetylcysteine poten-
tiated the platelet inhibitory actions of nitroglycerin by 
inducing the formation of S-nitroso-N-acetylcysteine. Im-
portantly, by illustrating that the concentration of inhibitor 
reducing aggregation response by 50% (IC50) for nitroglyc-
erin is up to two orders of magnitude lower in the presence 
of N-acetylcysteine, the discrepancy between achievable in 
vivo concentrations of nitroglycerin and the higher concen-
trations required for in vitro inhibition could be adequately 
explained. Thus, provided that sufficient reduced thiol is 
available, pharmacologically achievable concentrations of 
nitroglycerin significantly inhibit platelet aggregation in vitro 
(39,40). Gerzer eta!. (41) recently confirmed these observa-
tions by documenting a time-dependent liberation of nitric 
oxide from isosorbide dinitrate and nitroglycerin (as mea-
sured by guanylate cyclase activation and platelet inhibition) 
that is potentiated by cysteine. 
The observation that denitrification and nitric oxide lib-
eration from nitroglycerin are specifically dependent on the 
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availability of the reduced thiol cysteine (35 ,37 ,42) suggests 
that factors that can lead to its depletion, such as the act of 
phlebotomy and other lengthy preparative techniques, may 
account in part for the variability in the antiplatelet response 
to organic nitrates. Cysteine is present in low micromolar 
concentrations in plasma and its means of replenishment 
through hepatic sulfur metabolism (43) are obviously com-
promised ex vivo. In contrast, because liberation of nitric 
oxide from nitroprusside is independent of cysteine (31), the 
provision of reduced thiol ex vivo is not required to unmask 
its antiplatelet effects. This theory is compatible with the 
greater in vitro potency of nitroprusside than that of organic 
nitrates. However, reduced thiols play a complex and mul-
tifactorial role in the metabolism of nitroso compounds and 
also potentiate the antiplatelet actions of nitroprusside (39). 
The biochemical mechanism by which nitro(so)-vasodilators 
inhibit platelet activation and, specifically, the role of re-
duced thiol in the inhibition mediated by nitroglycerin and 
nitroprusside are summarized in Figure 1. 
Time dependence of nitric oxide elaboration from nitro-
glycerin. That nitric oxide liberation from nitroglycerin ap-
pears to be a time-dependent process (41) is also notewor-
thy. The usual evaluation of a drug's effect on platelet 
aggregation entails a brief preincubation period in platelet-
rich plasma before aggregation is induced by the addition of 
an agonist. The demonstration that the platelet-inhibitory 
effects of nitroglycerin after 1 h of incubation exceed those at 
2 min ( 41) provides an added explanation for the discrepancy 
between the relatively weak anti platelet effects of nitroglyc-
erin in previous in vitro studies in which preincubations have 
been of the order of minutes and its greater in vivo potency. 
Moreover, these data suggesting that nitric oxide generation 
from organic nitrates is slower than previously appreciated 
imply that the true in vitro antiplatelet profiles of nitroglyc-
erin and isosorbide dinitrate have not been fully elucidated. 
Cyclic GMP and platelet function. The biochemical and 
molecular mechanisms by which cyclic GMP modulates the 
intracellular events that follow receptor-mediated activation 
of platelets are an area of active investigation. The exposure 
of platelets to agonists of aggregation is associated with a 
burst in oxygen consumption, during which membrane 
arachidonate is converted to proaggregatory endoperoxides 
and thromboxane A2 (44). Thromboxane synthesis enhances 
calcium mobilization, which in turn induces platelet secre-
tion and promotes fibrinogen binding to the glycoprotein 
lib/Ilia complex on the platelet surface (44-46). Surface 
receptor activation also results in phosphoinositide hydrol-
ysis that facilitates calcium release from intracellular sites as 
well as platelet secretion (47). These inositol lipid-dependent 
functions are associated with phosphorylation of the platelet 
myosin light chain (20-kD protein) and a second 47-kD 
protein of unknown identity (47). 
Nitroglycerin, isosorbide dinitrate and isosorbide-5-
mononitrate attenuate the oxidation of arachidonate (23) and 
its conversion to thromboxane A2 and hydroxy-5,8,10,-
heptadecatrienoic acid (48) at concentrations that correlate 
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Figure 1. Schematic diagram of the proposed mechanism 
by which organic nitrates and related nitroso compounds 
inhibit platelet aggregation. Organic nitrates such as ni-
troglycerin (NTG) are metabolized to nitric oxide (NO), 
which complexes with the heme group of guanylate cy-
clase (GC) to activate the conversion of guanosine 
triphosphate (GTP) to cyclic guanosine monophosphate 
(cGMP). S-nitrosothiols (RSNO) are biologically active 
intermediates in this process, forming either extracellu-
larly from protein-bound or low molecular weight reduced 
thiol (RSH) such as cysteine or intracellularly from the 
reduced thiol glutathione in a reaction catalyzed by glu-
tathione-S-transferase. The generation of nitric oxide 
from nitroglycerin is also promoted by acidic conditions 
(H+) that facilitate conversion of nitrite (N02) through 
nitrous acid (HONO) to nitric oxide. Nitroprusside spon-
taneously releases nitric oxide and the pathway by which 
it inhibits platelet activation is presumed to resemble 
closely that of an endothelium-derived relaxing factor 
with chemical properties of nitric oxide. However, the 
mechanism by which these nitroso species traverse the 
lipid membrane and deliver nitric oxide to the effector 
guanylate cyclase is not well understood. The platelet also 
contains an endogenous mechanism (nitric oxide syn-
thase) for synthesis of nitric oxide from L-arginine, which 
may be involved in autoregulation of the aggregation 
response. CN5FeNo = nitroprusside; RSSR = disulfide; 
R-ON02 = organic nitrate. 
CN5 Fe NO -t-----R~S-N-0------./ 
(Nitroprusside) (?) 
with their in vitro potencies as platelet inhibitors 
(20,22,23,41). Organic nitrates and nitroprusside also inhibit 
agonist-provoked increases in platelet cytosolic free calcium 
in a cyclic GMP-dependent manner (49), thus potentially 
explaining the attenuation of platelet secretion by organic 
nitrates such as teopranitol (50). However, unlike the anal-
ogous inhibition of cytosolic calcium increases in response 
to calcium channel blockers, the effects of nitro compounds 
are not dependent on external calcium concentration (23). 
Accordingly, these observations suggest that cyclic GMP 
modulates intracellular platelet calcium availability by its 
interplay with phosphoinositide metabolism. Confirmatory 
evidence is provided by Deana eta!. (51), who have recently 
shown that nitroprusside and the 8-bromo analogue of cyclic 
GMP inhibit agonist-dependent phosphorylation of the 20-
and 47-kD proteins by interfering with the G-protein cou-
pling of the surface receptor to phosphoinositide turnover. 
Mendelsohn et al. (personal communication) have prelimi-
nary data in support of this observation, revealing that 
nitrosothiols retard phosphoinositide hydrolysis. In addi-
tion, these investigators (52) have observed that the in-
creases in cyclic GMP induced by S-nitroso-N-acetylcys-
teine correlate with inhibition of fibrinogen binding to the 
platelet surface glycoprotein lib/Ilia receptor, thereby pro-
viding a molecular basis for the inhibitory actions of nitrogen 
oxides on the platelet aggregation response. 
(GTP GC Mg••, RSH 
(guanylate cG M p 
cyclase) 
Effect on prostacyclin synthesis. Nitrates may inhibit 
platelets by indirect mechanisms that conceivably contribute 
to the alleged discrepancy between their in vivo and in vitro 
inhibitory potency. Interesting published studies addressing 
the effects of both organic nitrates and nitroprusside on 
endothelial prostaglandin metabolism support this conten-
tion. Levin eta!. (53) first reported in 1981 that nitroglycerin 
induces human umbilical vein endothelial cells to synthesize 
prostacyclin. Shortly thereafter, they (54) reported that 
nitroprusside did not alter prostacyclin metabolism under 
similar conditions. In 1985, the same group (55) admitted 
they were unable to confirm their original observations for 
nitroglycerin and that isosorbide dinitrate was an equally 
ineffective agent in this regard. However, by the time of this 
recantation, two other groups (56,57) had confirmed their 
initial observations, further fueling the controversy. 
Others (58,59) have since observed that the ability of 
nitrates to stimulate prostacyclin release is dependent on the 
presence of a free nitro group in an [exo] position, yet this 
mechanism does not fully explain the contradictory obser-
vations because this steric requirement is met by both 
nitroglycerin and isosorbide dinitrate. In reviewing 14 pub-
lications in favor of or against the nitroglycerin-prostacyclin 
hypothesis, Schror et al. (59) concluded that the use of 
different nitrate preparations may in part explain these 
discordant data. In keeping with this explanation, Gerzer et 
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al. (41) noted that batches of the same nitroglycerin formu-
lation varied in their capacity to activate platelet guanylate 
cyclase by as much as one order of magnitude. We have also 
observed significant variability in the activity of different 
nitroglycerin preparations and among batches of the same 
formulation; however, the molecular explanation for this 
variation is not yet understood. 
Synergistic inhibition of platelet function. The authors of 
several in vitro studies have argued that nitrogen oxides act 
synergistically with platelet-active prostaglandins to inhibit 
platelet aggregation. Levin et al. (54) suggested that nitro-
prusside interacts synergistically with prostacyclin to inhibit 
platelet function, MacDonald et al. (60) demonstrated "syn-
ergism" between nitric oxide and prostacyclin and De 
Caterina et al. ( 61 ,62) showed that isosorbide dinitrate and 
prostacyclin synergistically inhibit platelet aggregation. Al-
though each of these studies fails to meet strict pharmaco-
logic criteria for synergy (63), it is evident that prostacyclin 
enhances nitrate-mediated inhibition of platelet aggregation. 
We (64) recently demonstrated that nitroglycerin and pros-
taglandin E2 interact synergistically to disaggregate platelets 
and that synergism occurs over a narrow range of pharma-
cologically achievable concentrations in vitro. However, it 
remains to be established whether pharmacologically 
achieved concentrations of organic nitrates or nitroprusside 
interact synergistically with antiplatelet endothelial products 
in vivo. 
Antiplatelet action of metabolites of organic nitrates. De 
Caterina et al. (65) have raised the possibility that the 
antiplatelet properties of organic nitrates in vivo are a 
reflection of their metabolism to more active species. They 
demonstrated (62,65) that isosorbide-2-mononitrate inhibits 
platelet aggregation more effectively than does either iso-
sorbide dinitrate or isosorbide-5-mononitrate. Moreover, 
because both hepatic mononitrate metabolites are longer 
lived in vivo than is the dinitrate, they (62,65) propose that 
metabolite generation may account for differences in anti-
platelet potency in vivo and in vitro. The same may be 
true for nitroglycerin. It is well recognized that plasma levels 
of nitroglycerin correspond poorly with hemodynamic ef-
fects, an observation attributed to its complex hepatic and 
vascular smooth muscle metabolism (66,67). To our knowl-
edge, the antiplatelet effects of the various nitroglycerin 
metabolites have not yet been examined in vitro to test this 
hypothesis. 
Antiplatelet Effects of Organic Nitrates 
In Vivo and Ex Vivo 
Nitroprusside. In 1979, Mehta and Mehta (28) studied 11 
patients with congestive heart failure and 10 volunteers and 
convincingly demonstrated an antiplatelet effect for intrave-
nous nitroprusside infusions titrated to one of several hemo-
dynamic end points. This was evidenced by a decline in 
circulating platelet aggregates as well as ex vivo platelet 
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aggregation responses to adenosine diphosphate (ADP) and 
epinephrine. More recently, these findings were verified by 
Hynes and Barash (68) in 29 patients undergoing coronary 
artery bypass surgery. Infusions of nitroprusside for blood 
pressure control during anesthesia resulted in dose-related 
decreases in platelet aggregation to ADP and epinephrine 
and were accompanied by prolonged bleeding times. In 
agreement with the in vitro evidence for the guanylate 
cyclase-dependent mechanism of platelet inhibition by nitro 
compounds, Hogan et al. (69) demonstrated elevations in 
intracellular platelet cyclic GMP in association with platelet 
inhibition by infusion of nitroprusside. 
Isosorbide dinitrate and mononitrates. The data for iso-
sorbide dinitrate are equally impressive. De Caterina et al. 
(70) infused this agent into 11 volunteers with angina at 
4 mg/h for 30 min and demonstrated marked inhibition of ex 
vivo platelet aggregation and a decrement in circulating 
platelet aggregates. The nadir of the antiplatelet effect was 
delayed by 60 min from the time the infusion was terminated 
(that is, t = 90). Infusion at 30 mg/h for 20 min was often 
accompanied by a lesser antiplatelet effect attributed to 
excessive vasodilation that presumably evoked a compensa-
tory sympathetic (proaggregatory) response (70). In a more 
recent study (65), the same investigators examined the 
effects of isosorbide-2-mononitrate and isosorbide-5-
mononitrate infused at 4, 8 and 16 mg/h. Maximal ex vivo 
inhibition of platelet aggregation and thromboxane B2 pro-
duction were observed by 30 min after initiation of infusions 
and correlated in degree with hemodynamic changes (65). In 
contrast to the greater in vitro potency of isosorbide-2-
mononitrate, these two mononitrate species exhibited very 
similar in vivo profiles when infused intravenously (66). The 
effects of orally administered isosorbide were evaluated in 
one study (71) in which 20 mg of isosorbide-5-mononitrate 
did not inhibit platelet aggregation; however, hemodynamic 
effects were not documented. 
Reasons for lack of response to organic nitrates. In sum-
mary, data exist to support the view that nitroprusside and 
isosorbide dinitrate inhibit platelets in vivo. Their antiplate-
let effects seem to correspond with hemodynamic changes, 
as long as the latter are not excessive. The antiplatelet 
effects of isosorbide dinitrate are delayed, presumably as a 
function of the time to achievement of peak plasma levels, 
the time required for their conversion to active metabolites 
and metabolic delays in denitrification and reduction to nitric 
oxide (41). A few patients appear to be relatively insensitive 
to organic nitrates. In light of the critical reliance on cysteine 
for denitrification, a deficiency of this thiol may contribute to 
a lack of nitrate responsiveness. Thus, the characteristic 
impairment of cysteine synthesis in hyperhomocysteinemic 
states (72, 73) and the alterations in cysteine metabolism that 
may occur in hypertensive disorders (74) add yet another 
interesting twist to the concept of the "nitrate nonre-
sponder." 
Nitroglycerin. Available evidence also strongly supports 
an in vivo antiplatelet effect of nitroglycerin. Although these 
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data are more controversial, methodologic flaws readily 
account for the negative study results. Mehta and Mehta (29) 
reported that nitroglycerin infused intravenously at 55 ± 
7 JLg/min for a mean of 15 min, producing a decrease of 10 
and 5 mm Hg in capillary wedge and mean arterial pressure, 
respectively, did not significantly inhibit platelet aggregation 
or reduce circulating platelet aggregates in seven patients 
with congestive heart failure. To date, their study represents 
the major testimony against an in vivo antiplatelet effect of 
nitroglycerin. However, there are several potential reasons 
for this negative result. First, the preceding studies of 
isosorbide dinitrate suggest that the antiplatelet effects of 
organic nitrates are related to hemodynamic responsiveness 
and are dependent on the duration of nitrate therapy (65,70). 
In the study of Mehta and Mehta (29), the hemodynamic 
effects were modest, with no significant alterations in blood 
pressure or systemic vascular resistance, and the duration of 
the infusion was suboptimal. 
Low dose (5 JLglkg per min) nitroglycerin infusions in a 
canine model of coronary stenosis (75) likewise had negative 
results, as evidenced by the lack of change in cyclic platelet 
thrombus formation. In further examining the relation be-
tween the hemodynamic and platelet responses to nitroglyc-
erin in this canine model, we confirmed (76) that a 5-JLg/kg 
per min nitroglycerin infusion has little effect on either 
hemodynamic response or platelet aggregate formation. 
However, a 10-JLg/kg per min infusion evoking a detectable 
(but modest) decrease in blood pressure was associated with 
obliteration of cyclic flow variation (76). Moreover, in keep-
ing with the observations for isosorbide dinitrate, time 
dependence was demonstrated for the antiplatelet effects of 
nitroglycerin, which occurred maximally at approximately 
30 min (76). In five healthy volunteers receiving high dose 
nitroglycerin infusions, Fitzgerald et al. (77) noted that the 
subject exhibiting the greatest hemodynamic sensitivity to 
nitroglycerin also demonstrated marked inhibition of ex vivo 
platelet aggregation. In that study, the assessment of platelet 
function was performed after 1 h of continuous nitroglycerin 
therapy. 
Depletion of thiols during preparation of platelet-rich 
plasma ex vivo represents a second potential reason for 
the lack of observed platelet inhibition in the study of 
Mehta and Mehta (29). To assess this possibility in patients 
receiving nitroglycerin infusions titrated to a target systolic 
blood pressure, we repleted thiol stores with N-acetylcys-
teine ex vivo after preparing samples for platelet aggregation 
using standard techniques (40). In the absence of N-acetyl-
cysteine repletion, intravenous nitroglycerin exhibited little 
effect on platelet function; however, aggregation was signif-
icantly inhibited by the addition of N-acetylcysteine at 
concentrations that alone did not affect platelet aggregation. 
These supportive data notwithstanding, measurements of 
platelet and plasma thiols during preparatory techniques 
have not been made, and further studies are required to 
elucidate the relation between platelet and plasma thiol 
availability at rest and the subsequent capacity of added 
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reduced thiol to potentiate nitrate-mediated platelet inhibi-
tion. 
In this context, it is noteworthy that thiol repletion with 
N-acetylcysteine may act by one of several mechanisms to 
potentiate the effects of nitroglycerin, including enhanced 
conversion of nitroglycerin to nitric oxide (42); generation of 
the antiplatelet compound S-nitroso-N-acetylcysteine (39); 
prolongation of the half-life of nitric oxide derived from 
nitroglycerin by formation of S-nitroso-N-acetylcysteine or 
by scavenging inhibitory oxygen-centered free radicals (78); 
and reduction of critical thiol groups in guanylate cyclase 
itself, including dithiols at the active site and possibly an 
activator site thiol (79-81). 
The inability of Hogan et al. (82) to substantiate our 
findings in subjects receiving transdermal nitroglycerin 
(20 mg/24 h for 4 days) together with N-acetylcysteine 
(200 mg three times daily) is not surprising. This nitroglyc-
erin regimen has been determined to induce tolerance and 
therefore the investigators' failure to assess hemodynamic 
responsiveness as an indication of treatment efficacy is a 
major study weakness. Moreover, the dose of N-acetylcys-
teine is well below the established level of 100 to 200 mg/kg 
that is required to potentiate the hemodynamic (83,84) and 
anti platelet (76) actions of nitroglycerin in vivo. The conten-
tion that thiol depletion occurs ex vivo is further corrobo-
rated by the observations of Diodati et al. (85), who showed 
that platelet aggregation is attenuated in patients receiving 
intravenous nitroglycerin if it is measured in whole blood 
within 30 s of phlebotomy, whereas waiting 30 min results in 
loss of this effect. 
Role of prostacyclin in platelet inhibition by nitroglycerin. 
The results of Diodati et al. (85) are equally supportive of an 
alternative explanation for the discrepancy between the in 
vivo and in vitro antiplatelet potency of organic nitrates. 
Because the half-life ofprostacyclin is only 2 to 3 min (3,86), 
the loss of the ex vivo effects of nitroglycerin at 30 min in 
that study might be explained by the metabolism of prosta-
cyclin ex vivo. In further support of this notion, Davis et al. 
(71) observed that the ex vivo IC50 for prostacyclin in 
platelet aggregation studies is shifted leftward in patients 
receiving oral isosorbide-5-mononitrate. In addition, two 
studies have demonstrated that nitroglycerin given either 
sublingually (87) or intravenously (88) prolongs bleeding 
time. In the study by Ring et al. (87), aspirin-induced 
prolongation of bleeding time was potentiated by nitroglyc-
erin at 48 h but not at 2.5 to 3 h, therein corresponding 
with the time-dependent effects of aspirin on vascular endo-
thelial cell cyclooxygenase. Thus, these data collectively 
implicate a role for prostacyclin in platelet inhibition by 
nitroglycerin in human subjects. Although the data do not 
differentiate between nitroglycerin-prostacyclin synergism 
and the possibility of nitroglycerin-induced prostacyclin 
generation, other (albeit contradictory) in vivo studies 
(77 ,89-91) do not strongly support the latter mechanism. 
Thus, in effect, the data favor a synergistic action be-
tween nitroglycerin and prostacyclin that may contribute 
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to the greater in vivo than in vitro potency of organic 
nitrates. 
Relation of Organic Nitrate Metabolism and 
Action to Endothelium-Derived 
Relaxing Factor 
It is likely that the antiplatelet effects of organic nitrate 
derivatives reviewed here have a physiologic counterpart. 
Endothelium-derived relaxing factor (EDRF) (92), one form 
of which is nitric oxide or a nitroso compound, has been 
shown to inhibit platelet aggregation and adhesion ex vivo 
(93). Furthermore, we have shown that this effect is poten-
tiated by the reduced thiol N-acetylcysteine (94) in associa-
tion with an increase in intracellular platelet cyclic GMP 
levels, again substantiating the potential role of thiols and 
the cyclic GMP signal cascade in the biologic action of 
oxides of nitrogen (Fig. 1). 
Conclusions 
Platelet activation is a harbinger of morbidity and mor-
tality in several acute coronary ischemic syndromes (1-6,8). 
The use of aspirin in primary and secondary prevention trials 
(95-97) has been associated with a significant reduction in 
cardiovascular risk. However, it has not eliminated platelet-
related morbidity, a finding that is in keeping with the in vitro 
observations (98-100) that aspirin possesses limited anti-
platelet properties. 
Therapeutic trends in the setting of acute myocardial 
infarction reveal nitrate therapy to be the most frequent 
intervention and its use has increased dramatically over time 
(101). A recent meta-analysis (102) showed that the use of 
intravenous nitroglycerin and nitroprusside in patients with 
acute myocardial infarction is typically associated with a 
35% reduction in mortality, a degree of reduction that is 
unmatched by any of the existing accepted forms of therapy 
for acute myocardial infarction, including beta-adrenergic 
blockers and thrombolytic agents. Despite a general lack of 
objective evidence, recent recommendations (17,19) for ni-
trate therapy attest to the strong belief that these drugs are 
also beneficial in other ischemic syndromes in which plate-
lets play a central role. The evidence for the antiplatelet 
effects of organic nitrates and nitroprusside has been con-
clusively demonstrated. These drugs potently disarm plate-
lets of their ability to undergo primary and secondary wave 
aggregation (22,30,38,39), disperse already formed platelet 
clumps (30,64) and prevent platelet adhesion to damaged 
intimal linings (103,104). 
Accordingly, inhibition of platelet function is an impor-
tant property of organic nitrates and nitroprusside that more 
than likely contributes to their therapeutic efficacy in acute 
coronary syndromes. Thus, we advocate the use of nitrates 
as first-line agents in unstable angina and acute myocardial 
infarction. Prospective studies are needed to determine 
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dosing regimens that most efficaciously inhibit platelet func-
tion, as well as patient subsets that are most likely to benefit 
from the use of these agents for their antiplatelet properties. 
Nitrates should also be given consideration in future trials 
for primary prevention of vascular diseases in which plate-
lets have a proved role. 
We thank Stephanie Tribuna for excellent secretarial support. 
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